Brief: Bioarctic Says Novartis Terminates Option, Collaboration And License Agreement With Bioarctic
02/11/2026 20:32
BRIEF-Bioarctic Says Novartis Terminates Option, Collaboration And License Agreement With Bioarctic Nov 2 (Reuters) - BioArctic AB (publ) BIOAb.ST:
BIOARCTIC AB (PUBL) - NOVARTIS TERMINATES OPTION, COLLABORATION AND LICENSE AGREEMENT WITH BIOARCTIC
BIOARCTIC AB (PUBL) - TO RETAIN $30 MILLION UPFRONT PAYMENT AND RECOGNIZE REMAINING REVENUE IN 2026
BIOARCTIC AB (PUBL) - TERMINATION IS RESULT OF A NOVARTIS DECISION TO DISCONTINUE PROGRAM, UNRELATED TO BIOARCTIC'S BRAINTRANSPORTER TECHNOLOGY
Source text: ID:nWkrQRvB1
Further company coverage: [BIOAb.ST]
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: Bioarctic Says Novartis Terminates Option, Collaboration And License Agreement With Bioarctic
Brief: Bioarctic Receives Royalty Of SEK 203.8 Mln For Q3 Sales Of Leqembi
Brief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi